Tonsil Cancer Market is expected to grow at an approximate CAGR of ~4.6% | Top key Players - Amgen Inc, Abbott, Beckman Coulter Inc., AbbVie Inc. etc

Cancer is one of the major disease that has affected millions of lives all across the world. Especially, cancer has gained huge attention in last couple of decades due to the rapidly increasing number of people facing the consequences of the deadly disease. As a result, the research and development activities in the oncology have intensified in last decade.
According to National cancer Institute, in 2016, nearly 1,685,210 new cases of cancer were diagnosed in the United States and it was estimated that 595,690 people will die from the cancer.
Tonsil cancer begins in the cells of tonsils. It cause difficulty in swallowing and stimulates a feeling of something being stuck in the throat. Rise in the smoking, and alcohol consumption has increasd the risk of development of the tonsil cancer. Although some treatment options are available to manage the disease to a certain level, complete cure for the tonsil cancer is not yet available.

Try Sample Report Here @ https://www.marketresearchfuture.com/sample_request/4062 .

According to a recent study published by the Market Research Future analysts, the global tonsil cancer market is growing steadily; this steady growth is mainly to rising need for the better treatment options in cancer management, increased interest by the government in new company ventures and their R&D activities, financial support by the government.
That being said, there are some hurdles in the growth of the tonsil cancer market. These include adverse effects of the medication, extended time for approval of drugs, high cost of the treatment. These factors are more likely to thwart the growth of the market to an extent.
The global tonsil cancer market is expected to grow at the CAGR of ~4.6% during the forecast period and is estimated to reach USD 3396.3 million by 2023.

Key Players in the Global Tonsil Cancer Market
Some of the key players in this market: F. Hoffmann-La Roche Ltd (Switzerland), Amgen Inc. (US), Novartis AG(Switzerland), Abbott (US), Beckman Coulter Inc. (US), Debiopharm Group (Switzerland), AbbVie Inc. (US), Bayer AG (Germany, and others.

Global Tonsil Cancer Market - Competitive Analysis
The market for tonsil cancer is well established market with number of companies operating in this market which are developing products including the drugs, molecules.
Tonsil cancer Market is growing with increasing demand for the novel treatment options. Lack of availability of a concrete treatment option has created a wide range of opportunities for the development of the market. Companies are focusing on the development of new products which will be cost effective and will have minimum side effects. Various companies are involved in the development of specific types of molecules, and novel therapies.
In September 2017, Merck, an American pharmaceutical company, launched an anticancer drug, Keytruda in India

Regional Analysis of the Global Tonsil Cancer Market
The Americas dominate the global market for the tonsil cancer. North American countries like US dominates the market while Latin America region is also growing significantly in this region. The US is one of the top revenue generating countries in the global tonsil cancer treatment. Increasing number of patients with tonsil cancer is major driver for this market. North America is holding major market share due to some major factors like easily available treatment facilities, extended insurance cover, and adoption of advanced therapies to cure tonsil cancer.
Europe is the second largest market for tonsil cancer. This region is mainly divided into Eastern Europe and Western Europe. Germany is the largest while UK is the fastest growing market in Europe for tonsil cancer. As per the data published by Cancer Research UK, the incidence rate of head and neck cancer per 1,00,000 population in UK is 11,449 and cases are more in male than female. Availability of advanced healthcare facilities and high expenditure on healthcare are driving the growth for the market.
Asia Pacific region is one of the high potential market for healthcare sector. This region is showing exceptional growth in almost every product and services mainly related to medical field. Increasing cases of tonsil cancer, growing awareness among the patients and rapidly improving healthcare infrastructure are driving the market growth. Relatively low cost healthcare facilities are attracting patients from various high-income nations to get affordable treatments which boosting medical tourism in this region. Government is providing various subsidies and other facilities to improve public health as well as increasing use of insurance facilities are major driving forces for this market.
Lack of awareness of the disorder and limited availability of required healthcare facilities are major restraints for the Middle East & Africa tonsil cancer market due to which this market is expected to have limited growth during the forecast period.

Segments
The global tonsil cancer market is segmented on the basis of type, which comprises squamous cell carcinoma, salivary gland cancer, lymphoma, mucosal melanoma, sarcomas, malignant fibrous histiocytoma, Peripheral Neuroectodermal Tumor (PNET), and others. Sarcomas is further sub-segmented into chondrosarcoma, liposarcoma, synovial sarcoma, and others.
On the basis of diagnosis, the market is segmented into physical exam, imaging tests, removing a sample of tissue for testing, and others. Imaging tests is further sub-segmented into Computerized Tomography (CT), Magnetic Resonance Imaging (MRI) and Positron Emission Tomography (PET), and others.
On the basis of treatments, the market is segmented into surgery, radiation therapy, chemotherapy, rehabilitation, and others. Surgery is further sub-segmented into transoral surgery, transoral robotic surgery, open surgery, reconstructive surgery, and others. Radiation therapy includes external beam radiation therapy, internal radiation therapy, and others. Chemotherapy is further sub-segmented into alkylating agents, plant alkaloids, antitumor antibiotics, antimetabolites, topoisomerase inhibitors, miscellaneous antineoplastics, and others.
On the basis of end user, it is segmented into hospitals & clinics, medical research centers, academic institutes, and others.
In August 2016, two U.S. based pharmaceutical company Merck and Bristol Myer Squibb's sold block buster cancer drugs Keytruda and Opdivo respectively. Keytruda and Opdivo have generated global sales of USD 566 million and USD 942 million respectively.
In August 2016, Merck’s Pembrolizumab drug for the treatment of Head and Neck Cancer received approval from US FDA.
Additionally, a number of drugs are in the pipeline and is expected to launch soon in the market due to increasing need for the drugs. In coming years, introduction of the new and advanced drug may revolutionize the market.

Table of Content
1. Report Prologue

2. Introduction

2.1 Definition

2.2 Scope Of The Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

2.3 Market Structure

2.4. Market Segmentation

3. Research Methodology

3.1 Research Process

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

3.5 Forecast Model

4. Market Dynamics
….Continued

Get Discount on Report @ https://www.marketresearchfuture.com/check-discount/4062 .

About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.

Contact:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Maharashtra, India
+1 646 845 9312
Email: salesteam@marketresearchfuture.com

This release was published on openPR.